COST-UTILITY ASSESSMENT OF SIROLIMUS VERSUS TACROLIMUS FOR PRIMARY PREVENTION OF GRAFT REJECTION IN RENAL TRANSPLANT RECIPIENTS IN MEXICO

被引：1
|
作者：
Rely, K. [1 ]
Alexandre, P. K. [2 ]
Garcia-Garcia, E. G. [3 ]
Mucino-Ortega, E. [3 ]
Salinas-escudero, G. [4 ]
Galindo-Suarez, R. M. [3 ]
机构：
[1] CEAHealthTech, Mexico City, DF, Mexico
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Pfizer SA CV, Mexico City, DF, Mexico
[4] Hosp Infantil Mexico Dr Federico Gomez, Secretaria Salud, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.840
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A156 / A156
页数：1
相关论文
共 44 条
  • [21] Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function
    Vatsa Dave
    Kevan R. Polkinghorne
    Khai Gene Leong
    John Kanellis
    William R. Mulley
    [J]. Scientific Reports, 10
  • [22] Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function
    Dave, Vatsa
    Polkinghorne, Kevan R.
    Leong, Khai Gene
    Kanellis, John
    Mulley, William R.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] CYP3A5*1 Allele: Impacts on Early Acute Rejection and Graft Function in Tacrolimus-Based Renal Transplant Recipients
    Min, Sang-Il
    Kim, Seong Yup
    Ahn, Sang Hyun
    Min, Seung-Kee
    Kim, Si Hwa
    Kim, Yon Su
    Moon, Kyung Chul
    Oh, Jung Mi
    Kim, Sang Joon
    Ha, Jongwon
    [J]. TRANSPLANTATION, 2010, 90 (12) : 1394 - 1400
  • [24] The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function
    Knight, RJ
    Kerman, RH
    Schoenberg, L
    Podder, H
    Van Buren, CT
    Katz, S
    Kahan, BD
    [J]. TRANSPLANTATION, 2004, 78 (06) : 904 - 910
  • [25] Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function
    Liu, B
    Lin, ZB
    Ming, CS
    Zhang, WJ
    Chen, ZS
    Sha, B
    Zeng, FJ
    Chen, S
    [J]. TRANSPLANTATION PROCEEDINGS, 2003, 35 (01) : 87 - 88
  • [26] Correlating tacrolimus levels with dose formulation: implications for toxicity and renal graft rejection in a cohort of kidney transplant recipients with steroid-free maintenance immunosuppression.
    Gaitan-Torres, Natalia
    Lozano-Suarez, Nicolas
    Garcia-Lopez, Andrea
    Gomez-Montero, Andrea
    Giron-Luque, Fernando
    [J]. TRANSPLANTATION, 2024, 108 (09) : 172 - 172
  • [27] ASSESSING THE LIKELY COST-UTILITY OF ALEMTUZUMAB VERSUS RABBIT ANTI-THYMOCTE GLOBULIN AS INDUCTION THERAPY FOR HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS
    Tung, A.
    Devine, E.
    Garrison, L.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A294 - A294
  • [28] 6 months preliminary results of a randomized trial comparing sirolimus (SRL) versus tacrolimus (FK) in 141 transplant patients receiving a cadaveric renal graft.
    Glotz, D
    Charpentier, B
    Abramovicz, D
    Lang, P
    Rostaing, L
    Rifle, G
    Yves, V
    Berthoux, F
    Bourbigot, B
    Delahousse, M
    Chalopin, JM
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 460 - 460
  • [29] Daclizumab (humanized anti-IL2rα mab) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function
    Bumgardner, GL
    Ramos, E
    Lin, A
    Vincenti, F
    [J]. TRANSPLANTATION, 2001, 72 (04) : 642 - 647
  • [30] PREVENTION OF ACUTE GRAFT-REJECTION BY THE PROSTAGLANDIN-E1 ANALOG MISOPROSTOL IN RENAL-TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORINE AND PREDNISONE
    MORAN, M
    MOZES, MF
    MADDUX, MS
    VEREMIS, S
    BARTKUS, C
    KETEL, B
    POLLAK, R
    WALLEMARK, C
    JONASSON, O
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (17): : 1183 - 1188
12345